文献速递泌尿生殖与妇科肿瘤放疗

局限性前列腺癌质子治疗患者的早期毒性与患者报告生活质量:单机构前瞻性记录结局的回顾性分析

Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes.
PubMed 文献 · Radiat Oncol · 2018-09-17

本研究报告单机构2013至2016年接受质子束治疗(PBT)的局限性前列腺癌患者前瞻性采集的毒性与患者报告结局,最终分析192例随访超过1年的患者。中位随访1.7年,3级毒性见于5/192例,无4级或5级毒性;国际前列腺症状评分(IPSS)显示放疗后泌尿功能无变化。结论认为PBT治疗局限性前列腺癌后2年时3级或以上毒性罕见,需更长随访以进一步明确晚期毒性和生化控制。

要点

  • 192例局限性前列腺癌患者接受质子束治疗,中位随访1.7年,3级毒性见于5/192例,无4级或5级毒性。
  • IPSS评分显示放疗后泌尿功能无变化;中位SHIM评分在治疗后1年下降3.7分,1年后无进一步下降。
  • EPIC肠道领域评分从基线中位96分在治疗后1年平均下降5.4分(95%CI:2.5-8.2分,p<0.001),之后无进一步下降。

核心结论

  • 质子束治疗局限性前列腺癌后2年时3级或以上毒性罕见。
  • 需要更长随访以进一步明确晚期毒性和生化控制。

研究设计与样本

  • 单机构回顾性分析IRB批准的前瞻性登记注册数据,纳入2013至2016年接受质子束治疗的231例患者,最终分析192例随访超过1年的患者。
  • 毒性采用CTCAE v4.0前瞻性采集并评分,国际前列腺症状评分(IPSS)、男性性健康量表(SHIM)评分和扩展前列腺癌指数综合(EPIC)肠道领域问卷每次访视时收集。
  • 采用单因素Cox回归探索2级及以上毒性与临床、治疗和剂量学变量的关联。

主要发现

  • 中位随访1.7年,3级毒性见于5/192例患者,无4级或5级毒性。
  • IPSS评分显示放疗后泌尿功能无变化;中位SHIM评分在治疗后1年下降3.7分,1年后无进一步下降。
  • 单因素分析中仅较年轻年龄(HR=0.61,p=0.022)与性毒性降低相关。
  • EPIC肠道领域评分从基线中位96分在治疗后1年平均下降5.4分(95%CI:2.5-8.2分,p<0.001),之后无进一步下降。
  • 肠道毒性主要表现为一过性直肠出血,与抗凝药物使用相关(HR=3.45,p=0.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更长随访以进一步明确晚期毒性和生化控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We report prospectively captured clinical toxicity and patient reported outcomes in a single institutional cohort of patients treated for prostate cancer with proton beam therapy (PBT). This is the largest reported series of patients treated mostly with pencil beam scanning PBT. METHODS: We reviewed 231 patients treated on an IRB approved institutional registry from 2013 to 2016; final analysis included 192 patients with > 1-year of follow-up. Toxicity incidence was prospectively captured and scored using CTCAE v4.0. International Prostate Symptoms Score (IPSS), Sexual Health Inventory for Men (SHIM) score, and Expanded Prostate Cancer Index Composite (EPIC) bowel domain questionnaires were collected at each visit. Univariate Cox regression was used to explore associations of grade 2+ toxicity with clinical, treatment, and dosimetric variables. RESULTS: Median follow-up was 1.7 years. Grade 3 toxicity was seen in 5/192 patients. No grade 4 or 5 toxicity was seen. Patient reported quality-of-life showed no change in urinary function post-radiation by IPSS scores. Median SHIM scores declined by 3.7 points at 1-year post-treatment without further decrease beyond year 1. On univariate analysis, only younger age (HR = 0.61, p = 0.022) was associated with decreased sexual toxicity. EPIC bowel domain scores declined from 96 at baseline (median) by an average of 5.4 points at 1-year post-treatment (95% CI: 2.5-8.2 points, p < 0.001), with no further decrease over time. Bowel toxicity was mostly in the form of transient rectal bleeding and was associated with anticoagulation use (HR = 3.45, p = 0.002). CONCLUSIONS: Grade 3 or higher toxicity was rare at 2-years after treatment with PBT for localized prostate cancer. Longer follow-up is needed to further characterize late toxicity and biochemical control. TRIAL REGISTRATION: NCT, NCT01255748 . Registered 1 January 2013.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lee HJ, Macomber MW, Spraker MB, et al. Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes. Radiat Oncol. 2018. PMID: 30223877. doi:10.1186/s13014-018-1127-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。